Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 108Ovarian Neoplasms 64Neoplasms 61Fallopian Tube Neoplasms 40Lung Neoplasms 37Breast Neoplasms 33Neoplasm Metastasis 25Carcinoma, Ovarian Epithelial 25Triple Negative Breast Neoplasms 21Small Cell Lung Carcinoma 20Esophageal Neoplasms 19Endometrial Neoplasms 19Colorectal Neoplasms 15Advanced Solid Tumors 14Squamous Cell Carcinoma of Head and Neck 13Lymphoma, Large B-Cell, Diffuse 13Unspecified Adult Solid Tumor, Protocol Specific 12Stomach Neoplasms 11Melanoma 11Central Nervous System Neoplasms 11Uterine Cervical Neoplasms 10Pancreatic Neoplasms 10Astrocytoma 10Neuroblastoma 9Medulloblastoma 9Head and Neck Neoplasms 9Carcinoma 9Urinary Bladder Neoplasms 8Solid Tumors 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 8

Interventions

pembrolizumab 3blinatumomab 2enzalutamide 1durvalumab 1dostarlimab 1cemiplimab 1atezolizumab 1abiraterone 1N,N-dicyclohexyl-isoborneol-10-sulfonamide 1Immune Checkpoint Inhibitors 1Hydroxyurea 1Etoposide 1Etanercept 1Cytochrome P-450 Enzyme System 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Bites and Stings × Carboplatin × Clear all
NCT05361395 2026-03-03

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Amgen

Phase 1 Active not recruiting
184 enrolled
Thoracic

Bites and Stings, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡